Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ADC THERAPEUTICS SA

(ADCT)
  Report
Delayed Nyse  -  04:00 2022-11-28 pm EST
3.400 USD   -5.29%
11/28Biocytogen Enters into Antibody Agreement with ADC Therapeutics
BU
11/28ADC Therapeutics, Biocytogen Pharmaceuticals Sign Antibody License Deal for Tumor Targets
MT
11/14Sobi to present new data at the ASH 2022 Annual Meeting
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Days
:
Hours
:
Minutes
:
Seconds
Communiqués de presse de la société ADC THERAPEUTICS SA
11/28Biocytogen Enters into Antibody Agreement with ADC Therapeutics
BU
11/14Sobi to present new data at the ASH 2022 Annual Meeting
AQ
11/08Adc Therapeutics : Purchase Agreement - Form 6-K
PU
11/08ADC Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Upd..
BU
11/07ADC Therapeutics to Participate in the Jefferies London Healthcare Conference
BU
11/03ADC Therapeutics Announces Abstracts Accepted for Presentation at the 64th ASH Annual M..
BU
11/02IGM Biosciences and ADC Therapeutics Announce Clinical Collaboration Agreement to Evalu..
BU
11/02IGM Biosciences and ADC Therapeutics Announce Clinical Collaboration Agreement to Evalu..
AQ
11/01ADC Therapeutics Appoints Kristen Harrington-Smith as Chief Commercial Officer and Pete..
BU
10/31ADC Therapeutics to Host Third Quarter 2022 Financial Results Conference Call on Novemb..
BU
09/21ADC Therapeutics Announces Abstracts to be Presented at the Tenth Annual Meeting of the..
BU
09/16ADC Therapeutics and Sobi Announce ZYNLONTA® (loncastuximab tesirine) Receives Positive..
BU
09/07ADC Therapeutics to Participate in Morgan Stanley's 20th Annual Global Healthcare Confe..
AQ
09/06ADC Therapeutics to Participate in Morgan Stanley's 20th Annual Global Healthcare Confe..
BU
08/15Adc Therapeutics : WARRANT TO PURCHASE COMMON SHARES OF ADC THERAPEUTICS SA - Form 6-K
PU
08/15ADC Therapeutics Announces $175 million Senior Secured Term Loan from Owl Rock and Oakt..
BU
08/09Adc Therapeutics : Purchase Agreement - Form 6-K
PU
08/09ADC Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Up..
BU
08/02Adc Therapeutics : to Host Second Quarter 2022 - Form 6-K
PU
08/02ADC Therapeutics to Host Second Quarter 2022 Financial Results Conference Call on Augus..
BU
07/27Adc Therapeutics : Doses First Patient in Phase 1b Clinical Trial of ADCT-601 Targeting AX..
PU
07/27ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ADCT-601 Targeting A..
BU
07/20Adc Therapeutics : Announces First Patient Dosed in Phase 2 Clinical Trial of ZYNLONTA® (l..
PU
07/20ADC Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of ZYNLONTA® (..
BU
07/11Adc Therapeutics : Overland ADCT BioPharma Announces First Patient Dosed in China with ZYN..
PU
07/11Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA® in Combin..
BU
07/08Sobi to license loncastuximab tesirine from ADC Therapeutics
AQ
07/08ADC Therapeutics Announces Exclusive License Agreement with Sobi to Develop and Commerc..
BU
07/01ADC Therapeutics Appoints Jean-Pierre Bizzari, MD, to Board of Directors
BU
06/29ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ZYNLONTA® (loncastux..
BU
06/13Adc Therapeutics : Names David Gilman as Chief Business & Strategy Officer - Form 6-K
PU
06/13ADC Therapeutics Names David Gilman as Chief Business & Strategy Officer
BU
06/10ADC Therapeutics Announces Results from Pivotal Phase 2 Clinical Trial of Camidanlumab ..
BU
06/01Adc Therapeutics : to Present at the Jefferies Healthcare Conference - Form 6-K
PU
06/01ADC Therapeutics to Present at the Jefferies Healthcare Conference
BU
05/20Adc Therapeutics : To the shareholders of ADC Therapeutics SA - Form 6-K
PU
05/12ADC Therapeutics Announces Abstracts to be Presented at the European Hematology Associa..
BU
05/09ADC Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Upd..
BU
05/09ADC Therapeutics Announces CEO Transition
BU
05/04ADC Therapeutics to Present at the BofA Securities 2022 Healthcare Conference
BU
05/03ADC Therapeutics to Host First Quarter 2022 Financial Results Conference Call on May 9,..
BU
04/04ADC Therapeutics Receives Permanent J-Code for ZYNLONTA® (J9359) from U.S. Centers for ..
BU
03/17Adc Therapeutics : CEO Letter to Shareholders - Form 6-K
PU
03/17Adc Therapeutics : Releases its Annual Report on Form 20-F for the Fiscal Year Ended Decem..
PU
03/17ADC Therapeutics Releases its Annual Report on Form 20-F for the Fiscal Year Ended Dece..
BU
03/03Adc Therapeutics : Reports Fourth Quarter and Full Year 2021 Financial Results and Provide..
PU
03/03ADC Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provid..
BU
03/01Adc Therapeutics : to Participate in Cowen's 42nd Annual Health Care Conference - Form 6-K
PU
03/01ADC Therapeutics to Participate in Cowen's 42nd Annual Health Care Conference
BU
02/24Adc Therapeutics : to Host Fourth Quarter and Year-End 2021 - Form 6-K
PU
02/24ADC Therapeutics to Host Fourth Quarter and Year-End 2021 Financial Results Conference ..
BU
02/17Adc Therapeutics : Releases its Inaugural Environmental, Social and Governance Report - Fo..
PU
02/17ADC Therapeutics Releases its Inaugural Environmental, Social and Governance Report
BU
02/08ADC Therapeutics Highlights its Proprietary ADC Platform and Solid Tumor Pipeline
BU
02/02ADC Therapeutics to Participate in Guggenheim Oncology Conference
BU
02/02Adc Therapeutics : to Participate in Guggenheim Oncology Conference - Form 6-K
PU
01/20Adc Therapeutics : to Host Webcast Highlighting its ADC Platform and Solid Tumor Pipeline ..
PU
01/20ADC Therapeutics to Host Webcast Highlighting its ADC Platform and Solid Tumor Pipeline..
BU
01/19ADC Therapeutics Announces Exclusive License with Mitsubishi Tanabe Pharma Corporation ..
AQ
01/18ADC Therapeutics Announces Exclusive License with Mitsubishi Tanabe Pharma Corporation ..
BU
2021ADC Therapeutics to Participate in the Jefferies London Healthcare Conference - Form 6-..
PU
2021ADC Therapeutics to Participate in the Jefferies London Healthcare Conference
BU
2021ADC Therapeutics Announces Abstracts to be Presented at the 63rd ASH Annual Meeting - F..
PU
2021ADC Therapeutics Announces Abstracts to be Presented at the 63rd ASH Annual Meeting
BU
2021Purchase Agreement - Form 6-K
PU
2021ADC Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Upd..
BU
2021ADC Therapeutics Announces Validation of its Marketing Authorization Application by the..
PU
2021ADC Therapeutics Announces Validation of its Marketing Authorization Application by the..
BU
2021ADC Therapeutics to Host Third Quarter 2021 Financial Results Conference Call on Novemb..
PU
2021ADC Therapeutics to Host Third Quarter 2021 Financial Results Conference Call on Novemb..
BU
2021Lymphoma Hub maintains its focus on raising the levels of global knowledge of lymphoma ..
AQ
2021Adc Therapeutics : Overland ADCT BioPharma Announces First Patient Dosed in China with ZYN..
PU
2021Adc Therapeutics : Overland ADCT BioPharma Announces First Patient Dosed in China with ZYN..
BU
2021Adc Therapeutics : Doses First Patient in Phase 1 Clinical Trial of ADCT-901 in Advanced S..
BU
2021Adc Therapeutics : Doses First Patient in Phase 1 Clinical Trial of ADCT-901 in Advanced S..
PU
1  2  3Next